Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial - Zhu, A X; Kang, Y K; Yen, C J (Lancet Oncol, 2019)
et al.